Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Current Assets (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Current Assets for 7 consecutive years, with $797.7 million as the latest value for Q4 2025.

  • Quarterly Current Assets rose 10.69% to $797.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $797.7 million through Dec 2025, up 10.69% year-over-year, with the annual reading at $797.7 million for FY2025, 10.69% up from the prior year.
  • Current Assets hit $797.7 million in Q4 2025 for BridgeBio Pharma, down from $839.4 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $945.1 million in Q1 2021 to a low of $432.9 million in Q2 2023.
  • Historically, Current Assets has averaged $696.1 million across 5 years, with a median of $705.7 million in 2022.
  • Biggest five-year swings in Current Assets: tumbled 43.87% in 2023 and later skyrocketed 88.8% in 2025.
  • Year by year, Current Assets stood at $888.9 million in 2021, then tumbled by 38.25% to $548.9 million in 2022, then decreased by 12.98% to $477.6 million in 2023, then surged by 50.9% to $720.7 million in 2024, then grew by 10.69% to $797.7 million in 2025.
  • Business Quant data shows Current Assets for BBIO at $797.7 million in Q4 2025, $839.4 million in Q3 2025, and $912.3 million in Q2 2025.